MX2015012716A - Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. - Google Patents

Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.

Info

Publication number
MX2015012716A
MX2015012716A MX2015012716A MX2015012716A MX2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A
Authority
MX
Mexico
Prior art keywords
dipyridamole
compositions
eye disorders
treating eye
topically
Prior art date
Application number
MX2015012716A
Other languages
English (en)
Spanish (es)
Inventor
Moshe Rogosnitzky
Original Assignee
Remedeye Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedeye Inc filed Critical Remedeye Inc
Publication of MX2015012716A publication Critical patent/MX2015012716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2015012716A 2013-03-12 2014-03-11 Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. MX2015012716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compounds for use in ocular disorders using dipyridamole
PCT/IB2014/059645 WO2014141079A1 (fr) 2013-03-12 2014-03-11 Compositions destinées à être utilisées en traitement de troubles oculaires à l'aide de dipyridamole

Publications (1)

Publication Number Publication Date
MX2015012716A true MX2015012716A (es) 2016-07-06

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012716A MX2015012716A (es) 2013-03-12 2014-03-11 Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.

Country Status (14)

Country Link
EP (1) EP2968328A4 (fr)
JP (1) JP6820658B2 (fr)
KR (2) KR20210010638A (fr)
CN (1) CN105188702B (fr)
AU (1) AU2014229371B2 (fr)
BR (1) BR112015022084A2 (fr)
CA (1) CA2905594A1 (fr)
CL (1) CL2015002627A1 (fr)
EA (1) EA035966B1 (fr)
IL (1) IL225179A (fr)
MX (1) MX2015012716A (fr)
MY (1) MY182591A (fr)
SG (2) SG11201507092QA (fr)
WO (1) WO2014141079A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016119701A1 (fr) * 2015-01-28 2016-08-04 Realinn Life Science Limited Composés pour augmenter l'expression et la translocation nucléaire de pparγ et utilisation thérapeutique correspondante
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001805A1 (fr) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Formulations de dipyridamole stables et leurs procédés de préparation
WO2021001806A1 (fr) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Formulations de dipyridamole stables avec des impuretés réduites
WO2024125322A1 (fr) * 2022-12-16 2024-06-20 智泽童康(广州)生物科技有限公司 Dipyridamole pour prévenir et traiter des maladies allergiques et/ou inflammatoires et sa préparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (ja) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd ジピリダモールを必須成分とする眼圧降下剤
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
KR20080065704A (ko) * 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
WO2010056710A1 (fr) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions et procédés pour traiter des maladies ophtalmiques
EP2363126A1 (fr) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprenant une L-carnitine en tant que principe actif en combinaison avec le glucoside de l'hydroxykynurénine, pour la prévention et/ou le traitement de pathologies de l'oeil dues au rayonnement ultraviolet

Also Published As

Publication number Publication date
EA201591653A1 (ru) 2017-05-31
CN105188702A (zh) 2015-12-23
AU2014229371B2 (en) 2018-05-10
EP2968328A4 (fr) 2016-11-23
CL2015002627A1 (es) 2016-03-11
BR112015022084A2 (pt) 2017-07-18
SG10201706937UA (en) 2017-09-28
EP2968328A1 (fr) 2016-01-20
WO2014141079A1 (fr) 2014-09-18
EA035966B1 (ru) 2020-09-07
JP6820658B2 (ja) 2021-01-27
AU2014229371A1 (en) 2015-10-29
CN105188702B (zh) 2019-03-26
KR20150126021A (ko) 2015-11-10
SG11201507092QA (en) 2015-10-29
CA2905594A1 (fr) 2014-09-18
JP2016514123A (ja) 2016-05-19
IL225179A (en) 2017-01-31
MY182591A (en) 2021-01-26
IL225179A0 (en) 2013-06-27
KR20210010638A (ko) 2021-01-27

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX2015010125A (es) Derivados de piridazinona-amidas.
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
EA201591628A1 (ru) Дейтерированный палбоциклиб
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UA115357C2 (uk) Похідні піридин-4-ілу
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
MX2016016404A (es) Metodos para el tratamiento del prurito.
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
EP2910247A4 (fr) Compositions pour prévenir ou traiter des troubles cutanés allergiques, contenant les agents gpcr19 comme ingrédients actifs
WO2019040105A3 (fr) Composés, sels de ces composés et procédés pour le traitement de maladies
EA201491878A1 (ru) Замещенные ксантиновые производные
MX366805B (es) Uso de sulfato de zinc coceth como un agente antibacteriano en contra de propionibacterium acnes.
MX2016014261A (es) Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis.
NZ764041A (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis